CancerNCT07535918
Using e-Technologies to Maximize Physical Activity After Cancer Treatment
A study testing Cancer Exercise App in people with Cancer, run by University of Florida.
Trial summary
The Cancer Exercise app (CEA) is designed to promote physical activity among cancer survivors. The proposed randomized controlled clinical trial will investigate, in adults who have completed cancer treatment, the effects of a 12-week home-based exercise program, delivered using CEA, on physical activity levels. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Cancer
- What is being tested?
- Cancer Exercise App
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 750 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 to 85 years of age
- Diagnosed with stage I-III cancer
- Completed all primary cancer treatments (e.g., surgery, radiation, chemotherapy) at least 6 months prior to enrollment. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, immunotherapy, and bisphosphonates are allowed within 6 months of study enrolment and during study participation.
- Own a smartphone with data plan or access to WiFi (Apple or Android)
- Medical clearance provided or no medical clearance needed based on exercise preparticipation screening.
Who cannot join
- consistently engage in >300 min/week of moderate-intensity physical activity or 150 min/week of vigorous-intensity physical activity in the past 3 months
- receiving or scheduled to receive surgery or radiation during study participation
- have stage IV metastatic cancer or evidence of cancer recurrence
- have multiple myeloma
- have received bone marrow or hematopoietic stem cell transplant within past year
- are unable to walk without support or have severe weakness or balance problems that limit safe participation in exercise
Show all 9Show fewer
- contraindications to participate in unsupervised exercise
- are pregnant
- unable to read, speak and understand English
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Using e-Technologies to Maximize Physical Activity After Cancer Treatment: The eMPACT Trial
The Cancer Exercise app (CEA) is designed to promote physical activity among cancer survivors. The proposed randomized controlled clinical trial will investigate, in adults who have completed cancer treatment, the effects of a 12-week home-based exercise program, delivered using CEA, on physical activity levels. Participants will be randomized into one of two groups: (1) CEA or (2) Usual Care.
- Conditions
- Cancer
- Being tested
- Cancer Exercise App
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cancer Exercise AppBehavioural
Use of Cancer Exercise app to increase physical activity levels among cancer survivors.
| Study group | Role | What they receive |
|---|---|---|
| Cancer Exercise app group | Experimental | Not described Receives: Behavioral: Cancer Exercise App |
| Usual Care group | No intervention | Participants assigned to Usual Care group will receive no intervention. After completing the post-intervention assessments, they will be provided with information on how to download and use the Cancer exercise app. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in moderate to vigorous physical activity from pre- to post-intervention
Moderate to vigorous physical activity will be assessed using the International Physical Activity Questionnaire, a well-validated and reproducible questionnaire for use among cancer survivors
Measured: Baseline and following the 12-week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2026
- Study start1 Oct 2026 (estimated)
- Primary completionMay 2028 (estimated)
- Study completionMay 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University of FloridaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 750 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Florida
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Demetra Christou, PhD, Principal investigator, University of FloridaDanielle Jake-Schoffman, PhD, Principal investigator, University of Florida
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07535918
- Sponsor's protocol ID
- IRB202501619
- Status last verified
- May 2026
- First submitted
- 10 Apr 2026
- Last updated
- 27 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Using e-Technologies to Maximize Physical Activity After Cancer Treatment: The eMPACT Trial
- ClinicalTrials.gov ID
- NCT07535918
- Acronym / sponsor ID
- IRB202501619
- Conditions
- Cancer
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 750 participants (estimated)
- Lead sponsor
- University of FloridaUniversity, hospital or other
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- May 2028 (estimated)
- Study completion
- May 2028 (estimated)
- First posted
- 17 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Cancer Exercise app (CEA) is designed to promote physical activity among cancer survivors. The proposed randomized controlled clinical trial will investigate, in adults who have completed cancer treatment, the effects of a 12-week home-based exercise program, delivered using CEA, on physical activity levels. Participants will be randomized into one of two groups: (1) CEA or (2) Usual Care.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cancer Exercise app group | Experimental | Behavioral: Cancer Exercise App |
| Usual Care group | No intervention | –Participants assigned to Usual Care group will receive no intervention. After completing the post-intervention assessments, they will be provided with information on how to download and use the Cancer exercise app. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- 18 to 85 years of age
- Diagnosed with stage I-III cancer
- Completed all primary cancer treatments (e.g., surgery, radiation, chemotherapy) at least 6 months prior to enrollment. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, immunotherapy, and bisphosphonates are allowed within 6 months of study enrolment and during study participation.
- Own a smartphone with data plan or access to WiFi (Apple or Android)
- Medical clearance provided or no medical clearance needed based on exercise preparticipation screening.
Key exclusion criteria (9 listed)
- consistently engage in >300 min/week of moderate-intensity physical activity or 150 min/week of vigorous-intensity physical activity in the past 3 months
- receiving or scheduled to receive surgery or radiation during study participation
- have stage IV metastatic cancer or evidence of cancer recurrence
- have multiple myeloma
- have received bone marrow or hematopoietic stem cell transplant within past year
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cancer Exercise AppUse of Cancer Exercise app to increase physical activity levels among cancer survivors. | Behavioural | Cancer Exercise app group |
Primary outcome
Change in moderate to vigorous physical activity from pre- to post-intervention
Time frame: Baseline and following the 12-week intervention
Moderate to vigorous physical activity will be assessed using the International Physical Activity Questionnaire, a well-validated and reproducible questionnaire for use among cancer survivors
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingPhase 1/2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
RecruitingPhase 3
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Ovarian Cancer, Ovarian Neoplasms
RecruitingPhase 1/2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Lymphoma, Non-Hodgkin Lymphoma
RecruitingPhase 3
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Demetra Christou, PhD principal investigator
University of Florida
Danielle Jake-Schoffman, PhD principal investigator
University of Florida
Questions about this trial
What is this clinical trial studying?
A study testing Cancer Exercise App in people with Cancer, run by University of Florida.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Research Coordinator ((352) 294-1742, eMPACT@hhp.ufl.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in moderate to vigorous physical activity from pre- to post-intervention (time frame: Baseline and following the 12-week intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026.